Immunomics: discovering new targets for vaccines and therapeutics.
T-cell-epitope mapping has emerged as one of the most powerful new drug discovery tools for a range of biomedical applications. Initially, T-cell-epitope discovery was applied to the development of vaccines for infectious diseases and cancer. T-cell-epitope-mapping applications have now expanded to include reengineering of protein therapeutics (a process now called deimmunization), as well as the fields of autoimmunity, endocrinology, allergy, transplantation and diagnostics. Research employing T-cell-epitope mapping falls within the realm of immunomics, a new field that addresses the interface between host and (pathogen) proteome, bridging informatics, genomics, proteomics, immunology and clinical medicine. This review highlights aspects of recent immunomics research that are related to the discovery of the T-cell immunome.
De Groot
Anne S
AS
EpiVax, 146 Clifford Street, Providence, RI 02903, USA. AnnieD@EpiVax.com
D000890:Anti-Infective Agents / Q000276:immunology / Q000627:therapeutic use; D015551:Autoimmunity; D035843:Biomedical Research / Q000639:trends; D018604:Epitope Mapping; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D015202:Protein Engineering / Q000639:trends; D011506:Proteins / Q000276:immunology / Q000627:therapeutic use*; D020543:Proteome / Q000276:immunology*; D017634:Self Tolerance; D014612:Vaccines / Q000276:immunology*
D000890:Anti-Infective Agents; D018984:Epitopes, T-Lymphocyte; D011506:Proteins; D020543:Proteome; D014612:Vaccines